A novel ruthenium(III) complex with a tridentate dianionic P,O,O-ligand showing high cytotoxic activity

J.A. van Rijn; P. Marques Gallego; J. Reedijk; M. Lutz; E. Bouwman

A novel ruthenium(III) complex with a tridentate dianionic P,O,O-ligand showing high cytotoxic activity

J.A. van Rijn, P. Marques Gallego, J. Reedijk, M. Lutz, E. Bouwman

extern

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Tris(o-anisyl)phosphane was reacted with ruthenium(III) chloride forming a novel Ru(III) complex of formula [Ru(PAn3)(P(An)(phenolate)2)Cl] containing a tridentate dianionic P,O,O-ligand and a bidentate neutral P,O ligand. The tridentate ligand was formed by elimination of two methyl groups from the starting ligand in the reaction with the ruthenium salt. The molecular structure was determined by single crystal X-ray diffraction analysis. The compound shows a high cytotoxic activity in ovarian cancer cell lines comparable with cisplatin and overcoming cisplatin-resistance.

Original language	Undefined/Unknown
Pages (from-to)	10727-10730
Number of pages	4
Journal	Dalton Transactions
Volume	2009
Publication status	Published - 2009

Bibliographical note

Theme issue: Metal anticancer compounds

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Embargoed Document

B909520a
Final published version, 191 KB
Embargo ends: 1/01/50

Cite this

@article{23b282230c70465eb3d85c1cd92414a8,

title = "A novel ruthenium(III) complex with a tridentate dianionic P,O,O-ligand showing high cytotoxic activity",

abstract = "Tris(o-anisyl)phosphane was reacted with ruthenium(III) chloride forming a novel Ru(III) complex of formula [Ru(PAn3)(P(An)(phenolate)2)Cl] containing a tridentate dianionic P,O,O-ligand and a bidentate neutral P,O ligand. The tridentate ligand was formed by elimination of two methyl groups from the starting ligand in the reaction with the ruthenium salt. The molecular structure was determined by single crystal X-ray diffraction analysis. The compound shows a high cytotoxic activity in ovarian cancer cell lines comparable with cisplatin and overcoming cisplatin-resistance.",

author = "{van Rijn}, J.A. and {Marques Gallego}, P. and J. Reedijk and M. Lutz and E. Bouwman",

note = "Theme issue: Metal anticancer compounds",

year = "2009",

language = "Undefined/Unknown",

volume = "2009",

pages = "10727--10730",

journal = "Dalton Transactions",

issn = "1477-9226",

publisher = "Royal Society of Chemistry",

}

TY - JOUR

T1 - A novel ruthenium(III) complex with a tridentate dianionic P,O,O-ligand showing high cytotoxic activity

AU - van Rijn, J.A.

AU - Marques Gallego, P.

AU - Reedijk, J.

AU - Lutz, M.

AU - Bouwman, E.

N1 - Theme issue: Metal anticancer compounds

PY - 2009

Y1 - 2009

N2 - Tris(o-anisyl)phosphane was reacted with ruthenium(III) chloride forming a novel Ru(III) complex of formula [Ru(PAn3)(P(An)(phenolate)2)Cl] containing a tridentate dianionic P,O,O-ligand and a bidentate neutral P,O ligand. The tridentate ligand was formed by elimination of two methyl groups from the starting ligand in the reaction with the ruthenium salt. The molecular structure was determined by single crystal X-ray diffraction analysis. The compound shows a high cytotoxic activity in ovarian cancer cell lines comparable with cisplatin and overcoming cisplatin-resistance.

AB - Tris(o-anisyl)phosphane was reacted with ruthenium(III) chloride forming a novel Ru(III) complex of formula [Ru(PAn3)(P(An)(phenolate)2)Cl] containing a tridentate dianionic P,O,O-ligand and a bidentate neutral P,O ligand. The tridentate ligand was formed by elimination of two methyl groups from the starting ligand in the reaction with the ruthenium salt. The molecular structure was determined by single crystal X-ray diffraction analysis. The compound shows a high cytotoxic activity in ovarian cancer cell lines comparable with cisplatin and overcoming cisplatin-resistance.

M3 - Article

SN - 1477-9226

VL - 2009

SP - 10727

EP - 10730

JO - Dalton Transactions

JF - Dalton Transactions

ER -